Arca
Skip to content
Tools
Tools

Acute promyelocytic leukemia

Drug research and approvals for acute promyelocytic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 9 studies of acute promyelocytic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 6 open orphan designations naming it.

  • Recruiting worldwide: 9
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 9 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 8

Phase 2 10

Phase 1 or earlier 11

How its trials ended

103 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 33 whose ending is known, 52% met their primary endpoint, 6% missed it and 42% stopped early.

  • Completed, result not reported3534%
  • Status unknown1817%
  • Met its primary endpoint1717%
  • Ongoing1717%
  • Stopped: other or unclear77%
  • Stopped: enrollment or feasibility44%
  • Missed its primary endpoint22%
  • Stopped: funding22%
  • Stopped: sponsor or business decision11%

FDA orphan designations

Approved first, then open designations, newest first
Jan 12, 2018TrisenoxIn combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is…Teva Branded Pharmaceutical Products R&D, Inc.Approved
Sep 25, 2000TrisenoxFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed…Teva Branded Pharmaceutical Products R&D, Inc.Approved
Nov 19, 2024Arsenic trioxideTreatment of acute promyelocytic leukemiaSDK Therapeutics, Inc.Designated
Nov 2, 2015Arsenic trioxideTreatment of acute promyelocytic leukemia.Quetzal Therapeutics, LLCDesignated
Nov 2, 2010MenatetrenoneTreatment of acute promyelocytic leukemia.NBI Pharmaceuticals, Inc.Designated
Oct 11, 2007TamibaroteneTreatment of acute promyelocytic leukemia (APL).CytRx CorporationDesignated
Jan 19, 2000PhenylbutyrateTreatment of acute promyelocytic leukemia.Elan Drug Delivery, Inc.Designated
Apr 10, 1992AlitretinoinTreatment of acute promyelocytic leukemiaLigand Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.